These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 16834839
21. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Chang J, Couture F, Young S, McWatters KL, Lau CY. J Clin Oncol; 2005 Apr 20; 23(12):2597-605. PubMed ID: 15452188 [Abstract] [Full Text] [Related]
22. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE. Support Care Cancer; 2007 Dec 20; 15(12):1385-92. PubMed ID: 17541653 [Abstract] [Full Text] [Related]
23. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Am J Kidney Dis; 2007 Dec 20; 50(6):989-1000. PubMed ID: 18037099 [Abstract] [Full Text] [Related]
26. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, Naso A, Rossi E, Formica M, Lombardi L, Rotolo U, Conte F. J Nephrol; 2008 Dec 20; 21(3):412-20. PubMed ID: 18587731 [Abstract] [Full Text] [Related]
27. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. 20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026 [Abstract] [Full Text] [Related]
28. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Macdougall IC, Temple RM, Kwan JT. Nephrol Dial Transplant; 2007 Mar 20; 22(3):784-93. PubMed ID: 16968726 [Abstract] [Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS. Crit Care Med; 2006 Jun 20; 34(6):1661-7. PubMed ID: 16607233 [Abstract] [Full Text] [Related]
31. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study. Heras P, Kritikos K, Hatzopoulos A, Mitsibounas D. Eur J Cancer Care (Engl); 2008 Nov 20; 17(6):619-23. PubMed ID: 18707619 [Abstract] [Full Text] [Related]
32. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P. Clin J Am Soc Nephrol; 2009 Nov 20; 4(11):1731-40. PubMed ID: 19808215 [Abstract] [Full Text] [Related]
33. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T. BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982 [Abstract] [Full Text] [Related]
34. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U, RUBRA Study Investigators. Am J Nephrol; 2008 Oct 25; 28(2):280-9. PubMed ID: 18004064 [Abstract] [Full Text] [Related]
35. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. J Clin Oncol; 2006 Mar 01; 24(7):1079-89. PubMed ID: 16505427 [Abstract] [Full Text] [Related]
36. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy. Spaëth D, Desablens B, Rodon P, Mennecier B, Oudard S, Moullet I, Ghomari K, Bergougnoux L, Bleuzen P, Jenabian A, Ifrah N. Oncology; 2008 Mar 01; 74(1-2):112-8. PubMed ID: 18547966 [Abstract] [Full Text] [Related]
37. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU. J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117 [Abstract] [Full Text] [Related]